This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Coronavirus-Affected MedTech Drags S&P 500 Index Down
by Trina Mukherjee
Amid uncertainty surrounding the coronavirus outbreak, here are a few S&P 500 MedTech stocks that took a hit.
Should You Invest in the Fidelity MSCI Materials Index ETF (FMAT)?
by Sweta Killa
Sector ETF report for FMAT
Ecolab (ECL) Earnings and Revenues Miss Estimates in Q4
by Zacks Equity Research
Strength in the Global Industrial arm drives Ecolab's (ECL) Q4 results.
Global Industrial Unit to Drive Ecolab's (ECL) Q4 Earnings
by Zacks Equity Research
Ecolab's (ECL) Q4 results are likely to reflect strength in core Global Industrial unit.
Ecolab's Eco-Flex Teat Dip to Boost Food & Beverage Segment
by Zacks Equity Research
The Eco-Flex Teat Dip launch is likely to expand Ecolab's (ECL) Food & Beverage product portfolio.
Should You Invest in the Fidelity MSCI Materials Index ETF (FMAT)?
by Zacks Equity Research
Sector ETF report for FMAT
Should You Invest in the Fidelity MSCI Materials Index ETF (FMAT)?
by Sweta Killa
Sector ETF report for FMAT
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab (ECL) slashes 2019 EPS view owing to foreign exchange headwinds.
Ecolab (ECL) Down 3.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ecolab (ECL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Near-Term Prospects Gloomy for Specialty Chemical Stocks
by Anindya Barman
Trade tariffs and raw material cost inflation pose as headwinds to the chemical specialty industry.
Ecolab (ECL) Earnings and Revenues Miss Estimates in Q3
by Zacks Equity Research
Global Industrial unit aid Ecolab's (ECL) Q3 results; 2019 EPS view slashed.
Ecolab (ECL) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Ecolab (ECL) delivered earnings and revenue surprises of -0.58% and -1.77%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Can Global Industrial Unit Drive Ecolab's (ECL) Q3 Earnings?
by Zacks Equity Research
Positive developments in the Global Industrial unit are expected to have driven Ecolab's (ECL) Q3 results.
Here's Why You Should Retain Ecolab (ECL) Stock For Now
by Zacks Equity Research
Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.
PQG or ECL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PQG vs. ECL: Which Stock Is the Better Value Option?
Ecolab's (ECL) Gallay Medical Buyout to Boost Healthcare Arm
by Zacks Equity Research
The addition of Gallay Medical is likely to boost Ecolab's (ECL) Healthcare offerings.
Cintas (CTAS) Shares Rises 49% YTD: What's Driving the Rally?
by Zacks Equity Research
Cintas (CTAS) rises year to date, outperforming the industry, the sector and the S&P 500. Solid product portfolio, acquired assets, shareholder-friendly policies and outlook are few driving factors.
Should You Invest in the Fidelity MSCI Materials Index ETF (FMAT)?
by Zacks Equity Research
Sector ETF report for FMAT
Ecolab's (ECL) Nalco Water Opens Customer Experience Center
by Zacks Equity Research
Ecolab (ECL) expects Nalco's water technologies to reduce freshwater usage by 20%.
Here's Why You Should Hold on to Ecolab (ECL) Stock Now
by Zacks Equity Research
Ecolab (ECL) continues to gain from robust product portfolio and strong international presence. However, forex remains a woe.
Ecolab (ECL) Up 1.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ecolab (ECL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ecolab (ECL) Expands Product Portfolio With New Technology
by Zacks Equity Research
Ecolab (ECL) made an enhancement in its healthcare offerings with new technology that will improve standard of care for hospitals.
AXTA vs. ECL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AXTA vs. ECL: Which Stock Is the Better Value Option?
Ecolab's Chemstar Buyout to Boost Food & Beverage Business
by Zacks Equity Research
Chemstar's flagship Sterilox Fresh to help boost Ecolab's (ECL) Food & Beverage unit.
The Zacks Analyst Blog Highlights: Comcast, Ecolab, General Dynamics, Illinois Tool Works and O'Reilly Automotive
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Comcast, Ecolab, General Dynamics, Illinois Tool Works and O'Reilly Automotive